Objective:To evaluate the efficacy and safety of recombinant activated human coagulation factor VII (rFVIIa, NovoSeven) in orthotopic liver transplantation. Methods:Prospectively,sixty patients were randomized to rFVIIa treatment group aprotinin group and control group.Coagulation variables and thromboelastography (TEG) parameters [reaction time (r),Clot lysis at 30 minutes (LY30%),and maximal amplitude (MA)] were recorded at described time points.Blood loss,transfusion requirements,hospital time,hospital cost and vascular complication were compared to controls. Results:Administration of rFVIIa significantly shortened the prolonged prothrombin time (PT) and reaction time (r),increase maximal amplitude (MA) significantly (P<005),whereas didn t influenced the activated partial thromboplastin time (APTT),fibrinogen (FIB),platelet count (PLT) and Clot lysis at 30 minutes (LY30%) (P>005).Aprotinin group only increase maximal amplitude (MA) and decrease Clot lysis at 30 minutes (LY30%).In contrast with the control group,Both the perioperative blood loss and transfusion requirements were significantly reduced in rFVIIa group and aprotinin group (P<005). Conclusion:This study demonstrated that rFVIIa rapidly improved the exogenous coagulation function,aprotinin slowly inhibits hyperfibrinolysis,Both of them obviously reduced operation bleeding,but never increased the postoperative vascular complications.Application of rFVIIa and aprotinin are effective and safe during orthotopic liver transplantation.